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Abstract 
Objectives To develop and manufacture both immediate and sustained release 
vaginal tablets containing the anticancer drug disulfiram, which has the potential to 
be used as a non-invasive treatment for cervical cancer. 
 Methods Disulfiram-loaded vaginal tablets were manufactured at pilot scale using 
the direct compression method. These tablets were tested in accordance with the 
European Pharmacopeia testing of solid dosage form guidelines. They were also 
tested using a bio relevant dissolution method as well as a dual-chambered release 
model designed to better mimic the dynamic nature of the vaginal vault.  
Key findings We have developed both immediate and sustained release vaginal 
tablets, which when manufactured at pilot scale are within the limits set by the 
European Pharmacopeia for the testing of solid dosage forms. Furthermore, these 
tablets are capable of releasing disulfiram in vitro using the dual-chambered release 
model at levels 25 000 times and 35 000 times greater than its IC50 concentration 
for the HeLa cervical cancer cell line.  
Conclusions The successful pilot manufacture and testing of both the immediate 
and sustained release disulfiram-loaded vaginal tablets warrant further investigation, 
using an in-vivo model, to assess their potential for use as a non-invasive treatment 
option for cervical cancer. 
   
1. Introduction 
Cervical cancer is officially the third most prevalent cancer in women globally, with 
529,000 cases a year, 275,000 of which result in death.  It is especially dominant in 
developing countries where approximately 85 per cent of cases arise due to the lack 
of cervical cancer prevention and control programs.  In developed countries, where 
women have access to resources capable of detecting and treating precancerous 
lesions, the number of cases is reduced by approximately 80% [1]. The main cause 
of cervical cancer is the sexual transmission of the human papillomavirus (HPV).  
Approximately 15 HPV types are classed as carcinogenic or high-risk.  However 
types 16 and 18 are the most carcinogenic and are the main contributors to cervical 
cancer [2]. HPVs are small double-stranded DNA viruses that have the ability to 
infect epithelial cells in the cervix after entering a host through sexual contact [3]. 
The infected individual will produce antibodies as an immune response to the 
infection [3]; therefore most HPV infections are temporary and will be resolved within 
6 to 12 months. However, persistent HPV infections have the potential of causing the 
development of precancerous lesions and cervical intraepithelial neoplasia (CIN) that 
may lead to cervical cancer [4]. Many other risk factors, such as sexual activity at a 
young age, multiple sex partners, multiple pregnancies, smoking, oral contraceptives 
and other sexually transmitted infections can also contribute to cervical cancer [2-3]. 
 
In carcinoma in situ (stage 0), abnormal cells are found in the innermost lining of the 
cervix. These abnormal cells may become cancerous and spread into nearby normal 
tissue.  Stage I cancer is found in the cervix only and can be divided into stages IA 
and IB depending on the amount of cancer found.  These can be further divided into 
stages IA1, IA2, IB1 and IB2 depending on the size of the tumour.  In stage II the 
cancer has spread beyond the cervix but not as far as the pelvic wall or the lower 
third of the vagina.  Stage II is also divided into IIA and IIB, based on how far the 
cancer has spread.  In stage III the cancer has spread to the lower third of the vagina 
and/or pelvic wall and may also have started to cause kidney problems.  Like stage 
II, stage III is also divided into stages IIIA and IIIB, based on how far the cancer has 
spread.  By stage IV the cancer has spread to bladder, rectum or other parts of the 
body.  Stage IV can also be divided into IVA and IVB, depending on where the 
cancer is found.  In stage IVA the cancer has spread to nearby organs such as the 
bladder and rectum, while in stage IVB, the cancer may be found in other parts of the 
body, such as the liver, lungs, bones or distant lymph nodes.        
 
In developed countries, there are currently two methods used to prevent cervical 
cancer from developing to an advanced stage:  (1) the distribution of HPV vaccines 
that are mainly directed against HPV types 16 and 18 [5] and (2) screening methods, 
such as Papanicolaou test (Pap smear), which involves the collection of exfoliated 
cells from the cervix, which are then examined for cellular abnormalities. This 
enables identification of CIN before they begin to develop into cervical cancer [6].  
 
Following the diagnosis of cervical cancer there are many different treatment options 
and methods available, which depend on the stage of the cancer and whether or not 
the woman would like the option to be able to have children after treatment. 
Treatments for pre-invasive cancer (stage 0) include loop electrosurgical excision 
procedure (LEEP), large loop excision of the transformation zone (LLETZ) or cone-
shaped excision and involve the removal of a small amount of cervical stroma [7].  
Microinvasive cancer (stage IA) is treated by a hysterectomy (removal of the whole 
uterus including part of the vagina), while in stage IA2 cancers, the lymph nodes are 
removed as well. Early stage cancers (1B1 and IIA1) can be treated with a radical 
hysterectomy and removal of the lymph nodes or using radiation therapy, which may 
be given using external beam radiotherapy to the pelvis and/or brachytherapy via the 
vagina.  Patients treated using surgery may also receive radiation therapy in order to 
reduce the risk of relapse.  Larger early stage cancers (IB2 and IIA2) are treated with 
either radiation therapy or chemotherapy or a hysterectomy followed by radiation 
therapy, or chemotherapy followed by a hysterectomy.  Advanced stage cancers 
(IIIA to IVB) are treated using radiation therapy and chemotherapy [8].  All of these 
treatment options are either very invasive or involve extended stays in or repeated 
visits to the hospital.  The location of the cervix makes it easily accessible through 
the vagina and allows for non-invasive localised delivery of chemotherapeutic drugs, 
which offers a number of advantages over systemic administration, which include 
increased drug stability as it remains in the delivery device until released, direct 
delivery to the site of action, lower dose of drug required and reduced side effects 
due to the avoidance of systemic circulation [9]. Furthermore, cervical cancer is an 
excellent choice for localised drug delivery as due to regular screening 
approximately 50% of cases are diagnosed when the cancer is confined to the cervix 
(localised; stage I), while about 35% of cases are diagnosed after the cancer has 
spread to the lymph nodes (regional; stage II/III).  Therefore, only about 10% of 
cases are diagnosed when the cancer has already spread to distant regions 
(metastasized; stage IV).      
 
The vagina has been used to deliver drugs for a range of clinical and research 
applications, including contraception, vaginal infections and HIV prevention, with 
many different vaginal formulations such as gels, creams, pessaries, suppositories 
rings, films and tablets available [10-18].  However, only a small number of these 
delivery systems have been investigated for the localised delivery of 
chemotherapeutic drugs to the cervix [19-23].  The vaginal tablet is a very common 
dosage that are easy to manufacture, easy to place in the vagina and have a low 
cost of manufacture, making them ideal for use in developing countries.  
Conventional tablets for vaginal application may contain binders, disintegrants, and 
other excipients commonly used in tablets intended for oral administration.  As with 
most tablets the release rate can be varied by changes in the formulation or 
manufacturing process (i.e. the compression of the tablets).  Mucoadhesive 
polymers can be added to the formulation to help improve their retention time in the 
vagina.  Disulfiram is currently used for treating alcohol abuse as it can inhibit the 
enzyme aldehyde dehydrogenase that is responsible for metabolizing alcohol.  
However, disulfiram has shown potential anti-tumour activity as it can induce 
apoptosis in some cell lines and reduce cell growth in certain tumours [24]. 
Disulfiram is also capable of inhibiting activity of NFκB, a chemoresistant anti-
apoptotic factor found in many cancers [25]. An anticancer effect has been 
demonstrated in prostate cancer, breast cancer, lung cancer, leukaemia and cervical 
adenocarcinoma [25-32]. 
 
In this study we show, for the first time, the development and characterisation of both 
immediate and extended release vaginal tablets that are capable of releasing the 
chemotherapeutic drug disulfiram at levels well above its IC50 value for the HeLa 
cervical cancer cell line. 
  
2 Materials and Methods 
2.1 Materials  
Microcrystalline cellulose was purchased from Alfa Aesar (Lancashire, UK), Maize 
starch was obtained from Fisher Scientific (New Jersey, USA) and Lactose (α-D 
Lactose Monohydrate) was obtained from Acros Organics (Antwerp, Belgium). 
Methylcellulose, Kollidon® SR, Magnesium stearate, Stearic acid, Sodium Dodecyl 
Sulphate (SDS) and Disulfiram were purchased from Sigma-Aldrich, (Dorset, UK).  
All were used as supplied 
 
2.2 Determination of the IC50 value for Disulfiram on the HeLa Cervical 
Cancer Cell Line 
The HeLa cervical cancer cells were exposed to different concentrations of 
Disulfiram (n = 3) in combination with 10 µM of CuCl2 (10uM) for 72h and the 
concentration required to kill 50% of the cells was determined using the MTT cell 
proliferation assay. 
 
2.3 Determination of flowability, bulk and tapped density of the pre-
compression active mixes 
The active mixes where prepared in accordance with table 1 and the excipients 
where mixed together in a Speed Mixer DAC 15FVZ-K (Synergy Devices Ltd.) for 5 
min at 3500 RPM.  25 grams of each active mix was placed into the measuring 
cylinder of a Varian USP single-platform tapped density analyser. The bulk density 
was calculated by dividing the weight (g) by the volume (mL). The cylinder was then 
tapped and the volume measured at intervals of 10 taps and the tapped volume 
determined when there was no change in volume after 3 consecutive readings [33].  
The tapped density was calculated by dividing the weight (g) by the tapped volume 
(mL). The Carr’s index and Hausner ratio (calculated using equations 1 and 2, 
respectively) were used to determine the flowability of the active mixes. 
 
Equation 1:  Carr’s index = 100 X (1 – B/T) 
Equation 2:  Hausner ratio = T/B 
 
Where B is the bulk density of the active mix and T is the tapped density of the active 
mix 
 
The powder flow of the active mixes was evaluated using an Erweka GTL flowability 
tester, where 25 grams of each active mix was added to a dry funnel with the 
opening blocked.  The opening was then opened and the rate taken for the sample 
to flow out of the funnel was measured [34]. 
 
2.4 Manufacture of Disulfiram-Loaded Immediate and Extended 
Release Vaginal Tablets 
The active mixes where prepared in accordance with table 1 and the excipients 
where mixed together in a Speed Mixer DAC 15FVZ-K (Synergy Devices Ltd.) for 5 
min at 3500 RPM.  The active mixes where added to the hopper and compressed on 
an eight punch pilot scale tableting press (STC Rotary) to produce tablets of 
approximately 400mg. 
 
2.5 Determination of the hardness of Disulfiram-Loaded Immediate 
and Extended Release Vaginal Tablets 
 The mean hardness (n = 10) of the various tablets was measured with a tablet 
hardness tester (Varian VK 200). Each tablet was placed in the hardness tester and 
the maximum force in Newton required to break each tablet was measured [35].  
 
2.6 Determination of the friability of Disulfiram-Loaded Immediate and 
Extended Release Vaginal Tablets 
The friability of the Disulfiram-loaded immediate and extended release vaginal 
tablets was determined by placing ten pre weighed tablets with a collective weight of 
approximately 4 grams into the drum of a Charles Ischi AE-1 friability tester, which 
was subsequently rotated 50 times at a speed of 25 RPM. At the end of the test the 
tablets were dusted off and reweighed, the loss in the weight of tablet is the measure 
of friability and is calculated using equation 3.  A friability of less than 1.0% is 
deemed a pass, if the tablets passed the first time the test was repeated using the 
same tablets [36]. 
 
2.7 Uniformity of weight of Disulfiram-Loaded Immediate and 
Extended Release Vaginal Tablets 
Twenty randomly selected immediate and extended release tablets were individually 
weighed and their average weight determined [37].   
 
2.8 Content Uniformity of Disulfiram-Loaded Immediate and Extended 
Release Vaginal Tablets 
Ten individual tablets were crushed and the powder was dissolved in 1000mL of 2% 
SDS solution and filtered using a 0.45 micron filter before being analysed using the 
Disulfiram HPLC method [38]. 
 
2.9 Determination of the disintegration time of Disulfiram-Loaded 
Immediate and Extended Release Vaginal Tablets 
One tablet was place into each of six tubes (held in place with a disk) on the basket 
of a Varian VK 100 single basket tablet disintegration tester, before being suspended 
in a beaker containing 900mL of deionised water and the time taken for all tablets to 
disintegrate was recorded [39]. 
 
2.10 Dissolution of Disulfiram-Loaded Immediate and Extended Release 
Vaginal Tablets 
One pre-weighed tablet was placed into each of six vessels on a Varian 705 DS 
dissolution apparatus, which contained 900mL of 2% SDS solution heated to 37oC.  
The paddle speed was set at 100 RPM and 5mL samples were withdrawn (and 
replaced with pre-heated dissolution media) at 15 minute intervals and analysed 
using the Disulfiram HPLC method until approximately 100% of the total drug content 
was released [40].   
 
2.11 Biorelevant Dissolution of Disulfiram-Loaded Immediate and 
Extended Release Vaginal Tablets 
A biorelevant dissolution study was performed in order to resemble the aqueous 
environment and limited fluid levels of the vagina.  The tablets (n = 4) were placed 
into 8mL of deionised water and placed into an orbital shaking incubator (Innova 43) 
at 37oC and 60 rpm.  The release medium was sampled after 15, 30, 45, 60, 90, 120, 
240, 480 and 1440 minutes with complete replacement of the release medium and 
analysed using the Disulfiram HPLC method. 
 
2.12 In vitro release of Disulfiram-Loaded Immediate and Extended 
Release Vaginal Tablets using a dual chambered release method 
Two further mimic the dynamic nature of the vagina, were you have an aqueous 
environment (vaginal vault) surrounded by hydrophobic tissue, each Disulfiram-
loaded tablet (n = 4) was placed into a sealed latex balloon, with a 5 mm thick wall 
(to simulate vaginal tissue), containing 8 mL of water to simulate vaginal fluid.  The 
balloons where then submerged in 100 mL of 2% SDS solution (to simulate tissue) 
and placed into an orbital shaking incubator (Innova 43) at 37oC and 60 rpm.  2mL 
mL of sample was taken from the water and 5mL from the 2% SDS solution at 15, 
30, 45, 60, 90, 120, 240, 480 and 1440 minutes and replaced with fresh media.  The 
samples were analysed using the Disulfiram HPLC method.   
 
2.13 Disulfiram HPLC Methodology 
HPLC analysis was performed on an Agilent 1200 series HPLC with a Phenomenex 
Luna C18 4.6 x 150 mm column with a 5 µM particle size.  The mobile phase was 
comprised of 80% HPLC grade methanol and 20% HPLC grade water.  The flow rate 
was 1.00mL/min, while UV detection was performed at a wavelength of 275nm with 
an injection volume of 10µL. 
 
 
 
2.14 Statistical analysis 
 
Statistical analysis was performed using a one way analysis of variance (ANOVA) 
(GraphPad Prism version 5.02 for Windows, GraphPad Software, San Diego, CA).  
Post-hoc comparisons of the means were performed using Tukey’s Honestly 
Significance Difference test.  A significance level of p < 0.05 was accepted to denote 
significance in all cases. 
  
3 Results and Discussion 
3.1 Determination of the IC50 Value of Disulfiram on the HeLa Cervical 
Cell Line   
Figure 1 demonstrates that disufiram has a dose-dependent inhibition of the HeLa 
cervical cancer cell line with an IC50 value of 124.3nM (std dev 3.6).  Furthermore, it 
also demonstrates that disulfiram is much more potent against the HeLa cervical 
cancer cell line than it is against various breast cancer, glioblastoma and prostate 
cancer cell lines [25-29].  Disulfiram has been already been tested in both preclinical 
and clinical studies for its safety and effectiveness against a range of cancers, with 
promising results [30-32].  Therefore, due to its greater potency in cervical cancer 
cells, compared to other cell lines, it would make sense to develop a formulation 
capable of the localised delivery of disulfiram to the cervix for the treatment of 
cervical cancer and consequently we have developed both immediate and extended 
release disulfiram-loaded vaginal tablets. 
 
3.2 Flowability, bulk and tapped density of the pre-compression active 
mixes 
The successful manufacture of a tablet formulation is dependent on the flow 
characteristics of the powdered formulation [41].  The flow of a powder is important 
in determining its compression characteristics and poor powder flow can result in the 
tablets having varying weights, content uniformity, hardness, friability and dissolution 
rates [42].  Therefore, it is important to characterise and optimise powder flow in the 
manufacture of tablets. There are a number of methods commonly used to test 
powder flow; some examples include Carr’s compressibility index, Hausner ratio, 
angle of repose and flow-through-an-orifice [34, 43-45].  In this study we choose to 
use Carr’s compressibility index, the Hausner ratio and flow-through-an-orifice.  
Figure 2A demonstrates that the extended release active powder mix required less 
taps to become compacted and that the per cent volume change was much smaller 
when compared to the immediate release active mix (P values < 0.05).  Furthermore, 
the extended release active mix had a Carr’s index and Hausner ratio of 9.98 and 
1.03 respectively, which would suggest that it had excellent flow properties, while the 
Carrs’s index and Hausner ratio for the immediate release active where 14.87 and 
1.16 respectively giving it good flow properties (Figure 2B).  These results 
demonstrate that both active mixes are free flowing due to weak inter-particle forces 
and thus would be easily compressed on a tablet press.  This is further evident in 
figure 2C, which shows that both active mixes had average flow rates of 37.5 and 
27.5 g/s respectively, with standard deviations, after five readings, of zero, indicating 
an even and consistent flow of powder through the orifice of the funnel, which is 
within the specification limits of the European Pharmacopeia flowability monograph 
[34].  The reason for the extended release active mixes having a significantly higher 
flow rate (P values < 0.05) is due to the fact that it contains 37% of the excipient 
Kollidon® SR, which is a hydrophobic polymer used as a matrix in both extended 
and sustained release formulations.  Kollidon® SR has been shown to have 
excellent flow properties and can also enhance the flowability of other excipients in a 
tablet formulation [14]. 
 
3.3 Characterisation of Disulfiram-Loaded Vaginal Tablets 
3.3.1 Uniformity of Weight and Content Uniformity  
It is important that the tablets have uniformity of weight as this will provide an 
indication that the drug content within each tablet is also uniform.  Figure 3A 
demonstrates that both the immediate and extended release vaginal tablets comply 
with the European Pharmacopeia ‘uniformity of mass of a single-dose preparation’ 
monograph [37] as none of the individual tablets deviated from the average (421.7 
and 436.5) by more than 5%.  The difference in the average weight of the two tablet 
types (P values < 0.05) is due to the fact that the extended release active mix has 
better flow characteristics compared to the immediate release active mix (Figure 2B 
and C) and thus requires less agitation to become completely compacted (Figure 
2A).  Therefore, more of the extended release active mix will enter the die of the 
tablet press, which will result in the tablets having a greater mass. 
 
Based on the average weight of the tablets and drug loading of 30% the theoretical 
disulfiram content of both the immediate and extended release vaginal tablets should 
be 126.5 and 131.0 respectively.  Figure 3B demonstrates that the both the 
immediate and extended release tablets had an average drug content of 124.5 and 
133.0mg respectively.  Furthermore, both sets of tablets comply with the European 
Pharmacopeia Uniformity of Content of Single-Dose Preparations monograph as 
none of the 10 tablets tested were outside the specification limits of 85 to 115% of 
the theoretical content.  
 
3.3.2 Tablet Hardness and Friability 
Figure 3C demonstrates that the extended release tablets have a significantly higher 
hardness compared to the immediate release tablets (P values < 0.05), with values 
of 84.7 and 54.9N respectively.  The reason for this is that the extended release 
active mix has significantly higher flowability compared to the immediate release 
active mix (Figure 2C), which results in a higher compressibility index (Figure 2B), 
resulting in much harder tablets.  Furthermore, as has been mentioned previously, 
the extended release tablets contain 37% of the excipient Kollidon® SR, which has 
excellent flowability, compressibility and binding properties and thus will significantly 
contribute to the hardness of the tablet.  
  
The percent friability (Figure 3D), which is a method to determine the physical 
strength of tablets upon exposure to mechanical shock or agitation, was greater for 
the immediate release tablets compared to the extended release tablets.  This is 
because friability is related to tablet hardness - the harder the tablet the less friable it 
will be.  According to the European Pharmacopeia Friability of Uncoated Tablets 
monograph a percent friability of less than 1.0% is acceptable [36].  Therefore, both 
the immediate and extended release tablets are within the monograph’s 
specifications. 
 
3.3.3 Tablet Disintegration and Dissolution 
The disintegration of tablets is an important step in the dissolution process and is 
when the tablet breaks up into much smaller particles allowing for the increased 
release of drug.  According to the European Pharmacopeia Disintegration of Tablets 
and Capsules monograph, immediate release tablets must disintegrate within 15 
minutes, there is no requirement to test the disintegration rate of extended release 
tablets [39].  However, we tested our extended release tablets to see if they took 
significantly longer than the immediate release tablets to disintegrate, thus ensuring 
the extended release of disulfiram.  Figure 3E demonstrates that the immediate 
release tablets disintegrated within 13 minutes and thus where within specification, 
while the extended release tablets took 243 minutes to disintegrate, which is 
significantly longer than the immediate release tablets (P values < 0.05) and should 
result in the prolonged release of disulfiram. 
 
Figure 3F shows the percentage release of disulfiram from both the immediate and 
extended release vaginal tablets under sink conditions.  The immediate release 
tablet released approximately 100% of its disulfiram content within the first two 
hours, while it took up to four hours for the extended release tablet.  Looking at the 
extended release profile it would suggest that the drug is released at a zero-order 
release rate.  However, using the Korsmeyer–Peppas equation or power law, it was 
shown that the extended release tablets had an exponent n value of 1.23 (r2 0.99) 
which would suggest that the tablets exhibited Case-II transport release kinetics, in 
which the dominant mechanism for drug release is due to polymer relaxation as the 
Kollidon® (37% loading) swells.  This can be demonstrated by the change in 
thickness of the tablets from an average diameter of 12mm and a width of 4mm 
before release, which increased to 15 and 5.2mm respectively after release.  This 
was an increase of approximately 23% in diameter and 30% in width.  Furthermore, 
lactose (30% loading), due to its water soluble and hydrophilic nature, has been 
shown to enhance the swelling characteristics of tablets and is considered to be one 
of the better excipients at achieving controlled drug release from tablets 
manufactured using natural and/or synthetic controlled release polymers [46].  The 
immediate release tablets also exhibited Case-II transport release kinetics, 
particularly over the early stages of release, with an exponent n value of 1.67 (r2 
0.99).  This again is due to its high loading (27.9%) of lactose as well as methyl 
cellulose (25%), which is also known to cause tablets to swell.   
 
3.5 Biorelevant Dissolution of Disulfiram-Loaded Immediate and 
Extended Release Vaginal Tablets 
In order to replicate the aqueous environment and limited vaginal fluid levels of the 
vagina, as well as the constant replacement of vaginal fluid we placed the tablets 
into 8mL of water, with constant replacement of the release medium.  Figure 4A 
demonstrates that the immediate release tablets can achieve a disulfiram 
concentration (68.4 to 103.7 mM) greater than its IC50 value of 0.125mM.  However, 
after 8 hours of release the concentration to fall to below the IC50 value by 24 hours.  
The reason for the aforementioned release profile is because the immediate release 
tablets begin to disintegrate straight away(Figure 5A to E) releasing the disulfiram.  
However, after 8 hours the tablets have completely disintegrated (Figure 5F) and the 
debris from the tablet is removed from the release vessel upon replacement of the 
release media.  Therefore, the amount of drug available for release is decreased 
each time the release media is replaced.  This scenario would also happen in vivo as 
women produce about 6g of vaginal fluid per day, with about 0.5 to 0.75g present at 
any one time [47].  However, in figure 4A the extended release tablets release 
disulfiram at levels (67.5 to 630.4 mM) above the IC50 up to 24 hours when the 
release was stopped.  The reason for this is that the extended release tablets 
demonstrate minimal disintegration across the 24 hours of release (Figures 5G-M) 
and therefore minimal amounts of the tablets are removed upon replacement of the 
release media. Therefore, in vivo, the sustained release tablet should remain within 
the vagina and continue to release drug onto the cervix for length of time they are 
kept in place. 
 
The cumulative release data (Figure 4B) demonstrates that both the immediate and 
extended release tablets can achieve disulfiram concentrations well in access of the 
IC50 concentration after 24 hours of release, 814.6 and 1189.5 mM respectively.  
However, this only correlates to approximately 1.5 and 2.2% respectively of their 
total disulfiram content.  This is due to the low aqueous solubility of disulfiram which 
has a log P value of approximately 3.88.   
 
The vagina is a much more dynamic environment compared to the single 
compartment release study described above.  The vaginal vault may contain 
aqueous vaginal fluid, but it is a collapsed space surrounded by vaginal tissue which 
is much more hydrophobic.  Therefore, to represent the two compartments (aqueous 
vaginal vault surrounded by hydrophobic tissue) we used a more dynamic dual 
chambered release model consisting of a balloon filled with water to represent the 
aqueous vaginal vault, which was submerged in 100mL of 2% SDS solution to 
represent the hydrophobic tissue. 
 
3.6 In vitro release of Disulfiram-Loaded Immediate and Extended 
Release Vaginal Tablets using a dual chambered release model 
Figure 6A shows the release profile of disulfiram from both the immediate and 
extended release tablets into the balloon, which represents the aqueous vaginal 
vault, to be similar to their release profiles in figure 4A.  This is to be expected as the 
release rate of disulfiram is being controlled by its solubility in the aqueous media.  
However, figure 6B demonstrates that a much greater concentration of disulfiram is 
diffusing across the balloon wall (which represents the vaginal wall) and into the 2% 
SDS solution (which represents tissue absorption).  This dual chambered model 
demonstrates that both the immediate and extended release vaginal tablets can 
achieve tissue concentrations (3182.8 and 4410.8 mM respectively) well in access of 
the disulfiram IC50 for cervical cancers cells.              
  
4. Conclusion 
This paper demonstrates the development of both immediate and extended release 
vaginal tablets that are capable of delivering the chemotherapeutic drug disulfiram at 
levels significantly greater than its IC50 value for the HeLa cervical cancer cell ine.  
Furthermore, the powder formulations have both good and excellent flow properties, 
respectively, which allows them to be mass produced on an eight punch pilot scale 
tablet press and the subsequent tablets pass all European Pharmacopeia tests, with 
respect to hardness, friability, content uniformity, uniformity of weight, disintegration 
and dissolution.  We believe that these tablet formulations offer a non-invasive 
alternative to the current cervical cancer treatments available and the localised 
delivery should provide a better bioavailability of drug at the cancer site, while also 
minimising the systemic side effects associated with chemotherapeutic drugs.  	
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Table 1: 
Ingredient Immediate release active mix Extended release active mix 
Disulfiram 30.0% 30.0% 
Lactose 27.9% 30.0% 
Magnesium Stearate 0.6% 2.0% 
Kollidon® SR  37.0% 
Silicon Dioxide  1.0% 
Methyl Cellulose 25.0%  
Stearic Acid 1.5%  
Maize Starch 10.0%  
Microcrystalline Cellulose 5.0%  
 
